Excessive Pricing of Pharmaceuticals in the EU: Balancing between Exploitation and Exploitative Abuse

Normally, after the end of the exclusivity period offered by patents, medicines fall in public domain attracting competing companies to launch generic production that would bring down price levels. for different reasons, generic production of off-patented medicines does not always take place, allowi...

Full description

Bibliographic Details
Main Author:	Minn Mari
Format:	Article
Language:	English
Published:	Sciendo 2020-12-01
Series:	Baltic Journal of European Studies
Subjects:	balancing competition law eu exploitative abuse pharmaceuticals patents
Online Access:	https://doi.org/10.1515/bjes-2020-0023

id	doaj-c1be8bb9c86a4fe19a0a8802ece62860
record_format	Article
spelling	doaj-c1be8bb9c86a4fe19a0a8802ece628602021-07-01T05:21:49ZengSciendoBaltic Journal of European Studies2228-05962020-12-011039110810.1515/bjes-2020-0023Excessive Pricing of Pharmaceuticals in the EU: Balancing between Exploitation and Exploitative AbuseMinn Mari0Department of Law, Tallinn University of Technology, Akadeemia tee 3 Tallinn 12618, EstoniaNormally, after the end of the exclusivity period offered by patents, medicines fall in public domain attracting competing companies to launch generic production that would bring down price levels. for different reasons, generic production of off-patented medicines does not always take place, allowing the main producer to continue dictate price levels. under some circumstances, this conduct may turn into exploitative abuse. However, excessive pricing itself is not anti-competitive unless other cost-and non-cost-related factors are present that turn excessive pricing a concern of competition law.https://doi.org/10.1515/bjes-2020-0023balancing competition laweuexploitative abusepharmaceuticalspatents
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Minn Mari
spellingShingle	Minn Mari Excessive Pricing of Pharmaceuticals in the EU: Balancing between Exploitation and Exploitative Abuse Baltic Journal of European Studies balancing competition law eu exploitative abuse pharmaceuticals patents
author_facet	Minn Mari
author_sort	Minn Mari
title	Excessive Pricing of Pharmaceuticals in the EU: Balancing between Exploitation and Exploitative Abuse
title_short	Excessive Pricing of Pharmaceuticals in the EU: Balancing between Exploitation and Exploitative Abuse
title_full	Excessive Pricing of Pharmaceuticals in the EU: Balancing between Exploitation and Exploitative Abuse
title_fullStr	Excessive Pricing of Pharmaceuticals in the EU: Balancing between Exploitation and Exploitative Abuse
title_full_unstemmed	Excessive Pricing of Pharmaceuticals in the EU: Balancing between Exploitation and Exploitative Abuse
title_sort	excessive pricing of pharmaceuticals in the eu: balancing between exploitation and exploitative abuse
publisher	Sciendo
series	Baltic Journal of European Studies
issn	2228-0596
publishDate	2020-12-01
description	Normally, after the end of the exclusivity period offered by patents, medicines fall in public domain attracting competing companies to launch generic production that would bring down price levels. for different reasons, generic production of off-patented medicines does not always take place, allowing the main producer to continue dictate price levels. under some circumstances, this conduct may turn into exploitative abuse. However, excessive pricing itself is not anti-competitive unless other cost-and non-cost-related factors are present that turn excessive pricing a concern of competition law.
topic	balancing competition law eu exploitative abuse pharmaceuticals patents
url	https://doi.org/10.1515/bjes-2020-0023
work_keys_str_mv	AT minnmari excessivepricingofpharmaceuticalsintheeubalancingbetweenexploitationandexploitativeabuse
_version_	1721347322483310592

Excessive Pricing of Pharmaceuticals in the EU: Balancing between Exploitation and Exploitative Abuse

Similar Items